Anticancer potential of ferrocene-containing derivatives: Current and future prospective

• Published in: Journal of molecular structure 2025-01, Vol.1319, p.139589, Article 139589
• Main Authors: Tomar, Vijesh, Kumar, Parveen, Sharma, Deepak, Joshi, Raj K., Nemiwal, Meena
• Format: Article
• Language: English
• Subjects: Anti-cancer ferrocene; Cis-platin; Ferrocifen; Inhibitory concentration (IC50)
• ISSN: 0022-2860
• DOI: 10.1016/j.molstruc.2024.139589

•Ferrocenyl derivatives are attractive and interesting scaffolds for developing anticancer drugs for various cancer cell lines.•Ferrocene-phenol derivative known as ferrocifen is in the pre-clinical trial against breast cancer.•The structure-activity relationship with their IC50 value is disclosed. Organometallic compounds have gained popularity as potent anti-cancer therapeutic prospects in recent years. The constant threat of drug-resistant cancer and the limited specificity of anti-cancer drugs, which necessitate the urgent development of novel anti-cancer agents, are the principal obstacles to controlling and eradicating cancer. Primarily ferrocene derivatives, considered a prime example of an organometallic compound, have remarkable structural and mechanistic diversity, inherent stability against air and temperature, low toxicity, inexpensive, reversible redox properties, ligand exchange, and catalytic properties, making them promising potential drugs for cancer prevention and treatment. Significant effort has been made to isolate and synthesize ferrocene derivatives with improved anti-cancer activity due to the prospective utilization of ferrocene in the treatment of cancer chemotherapy. In order to assist both academics and researchers interested in the development of novel and effective pharmaceuticals to address cancer therapy in this discipline, we have focused our efforts in this review article on providing a broad overview of the most recent research publications of ferrocenyl moieties with potential applications in cancer treatment (2015-present). [Display omitted]